Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

OXYGENTA PHARMACEUTICAL LIMITE

Healthcare › Pharmaceuticals & Biotechnology
₹53.05
at close · 21 Sept 2026
▼ 0.15 (-0.28%)

Latest filings

  1. Oxygenta Pharma 33rd AGM: All 7 resolutions approved · Board & Shareholder Meetings
  2. Oxygenta Pharma 33rd AGM: all 7 resolutions passed including director appointments · Board & Shareholder Meetings
  3. Newspaper publication of 33rd AGM notice; AGM on 21 August 2026 · Compliance
  4. Book Closure and E-Voting Cut-off Date for 33rd AGM · Board & Shareholder Meetings
  5. Oxygenta Pharma files 33rd Annual Report for FY 2025-26, AGM on Aug 21 · Compliance
  6. 33rd AGM notice with director appointments and related party transactions · Board & Shareholder Meetings
  7. Board approves Q1 FY27 results, appoints cost auditor, AGM on 21 Aug · Management Changes
  8. Q1 FY27 revenue up 144 percent YoY, net loss narrows to Rs 210 lakhs · Results
  9. Q1 FY27 results: Revenue up 144% YoY, losses narrow · Results
  10. Board meeting postponed from 25 July to 27 July 2026 · Results
  11. Board meeting on 25 July 2026 to consider Q1 FY2027 results · Results
  12. Oxygenta Pharma files quarterly demat compliance certificate for June 2026 quarter · Compliance
  13. Trading window closed from July 1 ahead of Q1 FY27 results · Compliance
  14. Annual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations, 2018. · Compliance
  15. Change in Management by way of appointment of Additional Directors and Internal Auditor. · Management Changes
  16. Audited Financial Results for the Quarter and Year ended 31.03.2026. · Results
  17. Outcome of the Board meeting held on 23rd May, 2026. · Management Changes
  18. Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. Audited Financial .... · Results
  19. <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> .... · Compliance
  20. <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
  21. Compliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 31st March, 2026 · Compliance
  22. Closure of Trading Window for the period ending on 31.03.2026. · Compliance
  23. Disclosure under Regulation 30 of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015. · Regulatory & Legal
  24. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd · Ownership Changes
  25. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd · Ownership Changes
  26. Un-audited Results for the Quarter and nine months ended 31.12.2025. · Results
  27. With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, .... · Results
  28. Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and approve 1. Un-audited Financial .... · Results
  29. Compliance as per Regulation 74(5) of the SEBI (Depositories and Participants), Regulations, 2018 for the quarter ended 31st December, 2025. · Compliance
  30. Closure of Trading Window under SEBI (Prohibition of Insier Trading) Regulations, 2015 for the period ending on December 31, 2025. · Compliance
  31. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd · Ownership Changes
  32. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd · Ownership Changes
  33. Reclassification of promoters to public · Ownership Changes
  34. Minutes of the resolution passed by way Postal Ballot · Board & Shareholder Meetings
  35. Scrutinizer''s report of postal ballot · Ownership Changes
  36. Outcome of the Postal Ballot · Ownership Changes
  37. Submission of Newspaper Publications · Compliance
  38. Calendar of Events of Postal Ballot · Ownership Changes
  39. Notice of Postal Ballot - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclsoure Requirements), Regulations, 2015. · Board & Shareholder Meetings
  40. Appointment of Mr. Prasad Reddy Battinapatla as Chief Financial Officer of the Company · Management Changes
  41. Un Audited financial results for the Quarter and Half year ended 30.09.2025 · Management Changes
  42. Outcome of the Board meeting held on 07.11.2025 · Management Changes
  43. Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 ,inter alia, to consider and approve 1. Un-audited Financial .... · Results
  44. Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclsoure Requirement), Regulation, 2015. · Regulatory & Legal
  45. Intimation of Issuance of Duplicate Share Certificate · Compliance
  46. Compliance as per Regulation 74(5) of SEBI(Depositories and Participants), Regulations, 2018 for the Quarter ended 30th September, 2025. · Compliance
  47. Intimation of Receipt of No-objection from BSE Limited (BSE) for reclassification from "Promoter/ Promoter Group" Category to "Public" Category shareholder of the Company pursuant to Regulation .... · Ownership Changes
  48. Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015. · Compliance
  49. Secrutinzers Report and Voting Results for AGM held on 19.09.2025 · Board & Shareholder Meetings
  50. Outcome of the 32nd Annual General Meeting of the Company. · Board & Shareholder Meetings
All filings ↓
Ask Nexa about OXYGENTA PHARMACEUTICAL LIMITE

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures and sells pharmaceutical products from a base in Telangana (manufacturing licence no. 10/MD/AP/2013/B/G). It is a subsidiary of Virupaksha Organics Limited, which acquired a 56.5% stake in June 2025 and continues open-market buying; the board is seeking shareholder approval for related-party sales and purchases with Virupaksha Organics of up to Rs 250 crore and for loans and guarantees of up to Rs 200 crore in FY 2026-27. The product mix is not disclosed in the filings, but the cost shape — 97.7% materials as a share of FY26 revenue — points to a formulation or trading-led model with limited value-added processing. Revenue was Rs 11,298.19 lakhs in FY26 (up 3.4% YoY) but the company posted a net loss of Rs 1,757.17 lakhs, with finance costs rising sharply (nearly 4x to Rs 245.50 lakhs in Q1 FY27). Q1 FY27 revenue surged 144% YoY to Rs 3,699.69 lakhs while the net loss narrowed to Rs 210.37 lakhs. Borrowings climbed to Rs 10,956.68 lakhs by year-end FY26 (from Rs 6,193.24 lakhs) and the ECLGS scheme was drawn for Rs 399 lakhs; equity has turned negative at Rs -4,268.68 lakhs.

Operating scale
FY26 revenue
Rs 11,298.19 lakhsFY26
Q1 FY27 revenue YoY growth
144% (Rs 3,699.69 lakhs vs Rs 1,513.47 lakhs)Q1 FY27
Materials as % of revenue
97.7%FY26
Borrowings outstanding
Rs 10,956.68 lakhsFY26
ECLGS loan availed
Rs 399 lakhsFY27
Manufacturing licence suspension
7 days under Drugs and Cosmetics Act, 1940 (Licence 10/MD/AP/2013/B/G)FY26
Who pays it
Pharmaceutical buyers served via sales channels including related-party transactions with holding company Virupaksha Organics Limited (up to Rs 250 crore approved for FY27)
Biggest cost
Materials/raw materials at 97.7% of FY26 revenue (Rs 110.34 crore)
Kind of business
Loss-making, materials-heavy small-cap pharmaceutical manufacturer with negative net worth and rising borrowings
Where it sits
Telangana-based subsidiary of Virupaksha Organics Limited, which holds 56.5% as of February 2026; listed on BSE only (Scrip Code 524636)
Market Cap
₹196 Cr
P / E (TTM)
14.5×
EV / EBITDA
—
Div Yield
—
Growth
16.8%▲
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-35.0%·
ROCE (5y median)
ROE 25.0% · margin -13.3%
Leverage
-2.57·
Debt / Equity · low
Net debt ₹109 Cr
Revenue FY21→FY26
2.2×▲
Margin −21.2 pts
₹52 Cr → ₹113 Cr
Moves on a normal day
2.01%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#41/170
ROCE#178/183
ROE#9/171
Debt / Equity#1/171
EBITDA margin#153/165
Revenue growth#6/161
Profit growth#52/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Revenue compounding 17% a year over 5 years
Debt at -2.57× equity
lower than 100% of its 171 Pharmaceuticals peers
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Erratic profits — up in only 1 of the last 5 years
Returns on capital -35.0% (5-year median)
#178 of 183 in Pharmaceuticals on the latest reported figures · down from 32.8% in FY21
Customers are taking longer to pay — 11 → 32 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from OXYGENTA PHARMACEUTICAL LIMITE's filed financials and exchange disclosures

What does OXYGENTA PHARMACEUTICAL LIMITE do?

OXYGENTA PHARMACEUTICAL LIMITE is a Pharmaceuticals & Biotechnology company listed on BSE.

Is OXYGENTA PHARMACEUTICAL LIMITE profitable?

No. Over the trailing twelve months OXYGENTA PHARMACEUTICAL LIMITE reported a net loss of ₹14 Cr on revenue of ₹135 Cr.

Does OXYGENTA PHARMACEUTICAL LIMITE pay a dividend?

Not in the latest reported year — OXYGENTA PHARMACEUTICAL LIMITE's dividend payout for FY26 was nil.

Is OXYGENTA PHARMACEUTICAL LIMITE debt-free?

Effectively yes. Debt stands at -2.57× equity.

Is OXYGENTA PHARMACEUTICAL LIMITE expensive compared with its peers?

On trailing P/E, OXYGENTA PHARMACEUTICAL LIMITE ranks 41 of 170 in Pharmaceuticals — cheaper than 76% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.

How much does the OXYGENTA PHARMACEUTICAL LIMITE share price move in a day?

On a typical session OXYGENTA PHARMACEUTICAL LIMITE moves 2.01% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track OXYGENTA PHARMACEUTICAL LIMITE's announcements?

Every NSE and BSE filing by OXYGENTA PHARMACEUTICAL LIMITE appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.